Phase 1b/2a Study Assessing the Safety and Efficacy of Felzartamab in Anti-Phospholipase A2 Receptor Autoantibody-Positive Primary Membranous Nephropathy

By sjmartinez • September 19, 2024

Rovin BH, Ronco PM, Wetzels JFM, Adler SG, Ayoub I, Zaoui P, Han SH, Dudani JS, Gilbert HN, Patel UD, Manser PT, Jauch-Lembach J, Faulhaber N, Boxhammer R, Härtle S, Sprangers B. Phase 1b/2a Study Assessing the Safety and Efficacy of Felzartamab in Anti-Phospholipase A2 Receptor Autoantibody-Positive Primary Membranous Nephropathy. Kidney Int Rep. 2024 Jun 20;9(9):2635-2647. doi: 10.1016/j.ekir.2024.06.018. PMID: 39291206; PMCID: PMC11403052.

Tags: Clinical Trial, felzartamab, Harbor UCLA, MOR202, Nephrology, phase 2, phospholipase A2 receptor, primary membranous nephropathy, Publications

Clinical features, management, and outcomes of right heart thrombi: a retrospective cohort study

Fritzmann E, Yuen AD, Chang S, Yaqoob M, Kinninger A, Chung J, Vintch JRE, Matusov Y. Clinical features, management, and outcomes of right heart thrombi:[...]

Epigenetic Aging Clocks and Incident Cardiovascular Outcomes: Results From the MESA

Srivatsa S, Rice N, Pike JR, Smith JA, Ding J, Liu Y, Budoff M, Bey GS. Epigenetic Aging Clocks and Incident Cardiovascular Outcomes: Results From[...]

Low Prevalence of Coronary Artery Calcium in High Cardiometabolic Risk Kenyan Adults with and Without HIV: The ASANTE Study

Shah H, Krishnan S, Narashim A, Korir S, Omondi G, Maxime Ale B, Gitura BM, Kinuthia J, Farquhar C, Hsue PY, Budoff M, Longenecker CT,[...]